These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 10717501)
1. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. Kafetzis DA; Maltezou HC; Mavrikou M; Siafas C; Paraskakis I; Delis D; Bartsokas C Int J Antimicrob Agents; 2000 Feb; 14(1):51-5. PubMed ID: 10717501 [TBL] [Abstract][Full Text] [Related]
2. Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies. Maltezou HC; Baka M; Gombakis N; Koliouskas DE; Kosmidou H; Malaka-Zafiriou E; Kafetzis DA Int J Antimicrob Agents; 2001 Oct; 18(4):383-6. PubMed ID: 11691573 [TBL] [Abstract][Full Text] [Related]
3. A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. Viganò A; Principi N J Chemother; 1995 Jun; 7 Suppl 2():95-101. PubMed ID: 8622117 [TBL] [Abstract][Full Text] [Related]
4. Isepamicin versus amikacin in the treatment of urinary tract infection. Sturm W J Chemother; 1995 Jun; 7 Suppl 2():149-54. PubMed ID: 8622104 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections. Rodriguez-Noriega E; Esparza-Ahumada S; Morfin-Otero R J Chemother; 1995 Jun; 7 Suppl 2():155-60. PubMed ID: 8622105 [TBL] [Abstract][Full Text] [Related]
6. Once daily isepamicin treatment in complicated urinary tract infections. Lee SS; Liu YC; Wann SR; Lin WR; Tsai TH; Lin HH; Chen YS; Yen MY J Microbiol Immunol Infect; 1999 Jun; 32(2):105-10. PubMed ID: 11561574 [TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections. Leal del Rosal P J Chemother; 1995 Jun; 7 Suppl 2():143-8. PubMed ID: 8622103 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection. Colardyn F J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms. Covi M; Velluti G J Chemother; 1995 Jun; 7 Suppl 2():137-42. PubMed ID: 8622102 [TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Gram-negative bacteria to isepamicin: a systematic review. Falagas ME; Karageorgopoulos DE; Georgantzi GG; Sun C; Wang R; Rafailidis PI Expert Rev Anti Infect Ther; 2012 Feb; 10(2):207-18. PubMed ID: 22339194 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. Beaucaire G J Chemother; 1995 Jun; 7 Suppl 2():165-73. PubMed ID: 8622107 [TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy? Goodlet KJ; Benhalima FZ; Nailor MD Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397061 [TBL] [Abstract][Full Text] [Related]
13. Overview of the efficacy of isepamicin in the adult core clinical trial programme. Carbon C J Chemother; 1995 Jun; 7 Suppl 2():79-85. PubMed ID: 8622115 [TBL] [Abstract][Full Text] [Related]
14. The major aminoglycoside-modifying enzyme AAC(3)-II found in Escherichia coli determines a significant disparity in its resistance to gentamicin and amikacin in China. Xiao Y; Hu Y Microb Drug Resist; 2012 Feb; 18(1):42-6. PubMed ID: 22066787 [TBL] [Abstract][Full Text] [Related]
15. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli. Giamarellos-Bourboulis EJ; Baziaka F; Antonopoulou A; Koutoukas P; Kousoulas V; Sabracos L; Panagou C; Perrea D; Giamarellou H Int J Antimicrob Agents; 2005 Feb; 25(2):168-72. PubMed ID: 15664488 [TBL] [Abstract][Full Text] [Related]
16. Use of gentamicin for women with community-acquired uncomplicated acute pyelonephritis caused by gentamicin-susceptible or -resistant Escherichia coli: 10-year experience. Wie SH; Kim HW; Chang UI Microb Drug Resist; 2013 Aug; 19(4):316-22. PubMed ID: 23473263 [TBL] [Abstract][Full Text] [Related]
17. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Giamarellos-Bourboulis E; Adamis T; Sabracos L; Raftogiannis M; Baziaka F; Tsaganos T; Koutoukas P; Plachouras D; Karayannacos P; Giamarellou H Scand J Infect Dis; 2005; 37(1):48-54. PubMed ID: 15764190 [TBL] [Abstract][Full Text] [Related]
18. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients. Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099 [TBL] [Abstract][Full Text] [Related]
19. Use of cefuroxime for women with community-onset acute pyelonephritis caused by cefuroxime-susceptible or -resistant Escherichia coli. Chang UI; Kim HW; Wie SH Korean J Intern Med; 2016 Jan; 31(1):145-55. PubMed ID: 26767868 [TBL] [Abstract][Full Text] [Related]
20. Aminoglycosides Monotherapy as First-Line Treatment for Febrile Urinary Tract Infection in Children. Poey N; Madhi F; Biscardi S; Béchet S; Cohen R Pediatr Infect Dis J; 2017 Nov; 36(11):1104-1107. PubMed ID: 28498305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]